Scientific Reports (Mar 2023)

The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase

  • Siwaporn Boonyasuppayakorn,
  • Thanaphon Saelee,
  • Thao Nguyen Thanh Huynh,
  • Rita Hairani,
  • Kowit Hengphasatporn,
  • Naphat Loeanurit,
  • Van Cao,
  • Vipanee Vibulakhaophan,
  • Panattida Siripitakpong,
  • Parveen Kaur,
  • Justin Jang Hann Chu,
  • Chairat Tunghirun,
  • Opas Choksupmanee,
  • Sarin Chimnaronk,
  • Yasuteru Shigeta,
  • Thanyada Rungrotmongkol,
  • Warinthorn Chavasiri

DOI
https://doi.org/10.1038/s41598-023-32049-x
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Dengue and Zika viruses are mosquito-borne flaviviruses burdening millions every year with hemorrhagic fever and neurological symptoms. Baicalein was previously reported as a potential anti-flaviviral candidate and halogenation of flavones and flavanones potentiated their antiviral efficacies. Here, we reported that a chemically modified 8-bromobaicalein effectively inhibited all dengue serotypes and Zika viruses at 0.66–0.88 micromolar in cell-based system. The compound bound to dengue serotype 2 conserved pocket and inhibited the dengue RdRp activity with 6.93 fold more than the original baicalein. Moreover, the compound was mildly toxic against infant and adult C57BL/6 mice despite administering continuously for 7 days. Therefore, the 8-bromobaicalein should be investigated further in pharmacokinetics and efficacy in an animal model.